RenovoRx, Inc. (RNXT)
Chart Events
Performance Outlook
| Previous Close | 2.6800 |
| Open | 2.5600 |
| Bid | 2.5600 x 800 |
| Ask | 2.6700 x 1000 |
| Day's Range | 2.5100 - 2.7500 |
| 52 Week Range | 1.5000 - 5.7450 |
| Volume | |
| Avg. Volume | 58,498 |
| Market Cap | 23.972M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8700 |
| Earnings Date | Mar 02, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RNXT
Related Research
- RenovoRx, Inc.ANGO: Raising target price to $10.00ANGIODYNAMICS INC has an Investment Rating of SELL; a target price of $10.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.RatingFair ValueEconomic Moat3 days agoArgus Research
- News Direct
RenovoRx’s Principal Investigator of Phase III Clinical Trial Discusses Positive Interim Results on Patients with Locally Advanced Pancreatic Cancer on OncologyTube
In the interview, Dr. Michael Pishvaian discussed the trial's potential impact on the oncology community as well as how pancreatic cancer patients are treated.
- Benzinga
RenovoRx's Targeted Pancreatic Cancer Treatment Shows Positive Trend In Median Overall Survival Versus Standard Care
RenovoRx Inc (NASDAQ: RNXT) announced interim data in the Phase 3 open-label TIGeR-PaC clinical trial investigating the company's first product candidate, RenovoGem, as a potential treatment option in locally advanced pancreatic cancer (LAPC). The interim analysis suggests a 6-month potential improvement in median overall survival with RenovoGem. The study compares treatment with RenovoTAMP versus standard-of-care systemic intravenous administration of gemcitabine and nab-paclitaxel, which has a
- Business Wire
RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer
LOS ALTOS, Calif., March 08, 2023--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced promising interim data in the Phase III open label TIGeR-PaC clinical trial. The study is investigating the Company’s first product candidate, RenovoGem, as a potential treatment option in locally advanced pancreatic cancer ("LAPC").
